SCHEMBL1673585

SCHEMBL1673585

CC(C)(C)OC(=O)N1CCN(C(=O)OC(C)(C)C)[C@@H](c2ccc(N3CC[C@H](N4CCCC4)C3)cc2)C1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 5/20 0.46
NR1H3 Q13133 5/20 0.46
GPR119 Q8TDV5 8/20 0.45
MBTD1 Q05BQ5 1/20 0.41
TP53BP1 Q12888 1/20 0.41
L3MBTL4 Q8NA19 1/20 0.41
L3MBTL3 Q96JM7 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PDE4B Q07343 1/20 0.41
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
ABHD6 Q9BV23 1/20 0.39
USP30 Q70CQ3 1/20 0.39
ROCK2 O75116 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1673586 1.00 NR1H2 (0.46) NR1H2NR1H3GPR119MBTD1TP53BP1
SCHEMBL83999 0.86 GPR119 (0.48) NR1H2NR1H3GPR119PDE4BALDH1A1
SCHEMBL1673505 0.85 GPR119 (0.48) NR1H2NR1H3GPR119PDE4BALDH1A1
SCHEMBL1673508 0.85 GPR119 (0.48) NR1H2NR1H3GPR119PDE4BALDH1A1
SCHEMBL1673555 0.80 NR1H2 (0.50) NR1H2NR1H3GPR119
SCHEMBL1674907 0.80 NR1H2 (0.50) NR1H2NR1H3GPR119
SCHEMBL84000 0.80 NR1H2 (0.48) NR1H2NR1H3GPR119ALDH1A1LMNA
SCHEMBL22772313 0.78 NR1H2 (0.47) NR1H2NR1H3GPR119PDE4BALDH1A1
SCHEMBL83834 0.77 NR1H2 (0.59) NR1H2NR1H3PDE4BABHD6USP30
SCHEMBL521801 0.77 NR1H2 (0.49) NR1H2NR1H3GPR119L3MBTL1PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308854-A1 2,3,6-trisubstituted-4-pyrimidone derivatives Sanofi-Aventis (FR) 2011-04-13 EP disclosed
EP-2305651-A1 2,3,6-trisubstituted-4-pyrimidone derivatives Mitsubishi Tanabe Pharma Corporation (JP) 2011-04-06 EP disclosed
US-7504411-B2 2,3,6-Trisubstituted-4-pyrimidone derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-17 US disclosed
US-20060252768-A1 2,3,6-Trisubstituted-4-pyrimidone derivatives SANOFI (FR) 2006-11-09 US disclosed
EP-1608630-A1 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES Mitsubishi Pharma Corporation (JP) 2005-12-28 EP disclosed
WO-2004085408-A1 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES MITSUBISHI PHARMA CORPORATION (JP) 2004-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252768-A1 2,3,6-Trisubstituted-4-pyrimidone derivatives PSEN1, PSEN2, MAPT NR1H2 3604/4885NR1H3 3999/4885GPR119 1133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.